Dermatological conditions are one of the most common types of disorders worldwide, from which approximately more than half of the population suffers. For the past decades, the majority of the dermatology market has remained saturated with established products for example acne has reached it saturation with respect to its biologics and new product pipeline. Since R&D is a never ending process and has led to new product pipeline. The clinical and commercial success of biologics in the treatment of dermatological conditions, as well as advancements in the understanding of the disease pathways of many dermatological conditions, has led to a renewed interest of pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline. The prevalence of various skin disease varies according to geographical area, race, environment and other socioeconomic factors. Disease like eczema and dermatitis were known to be high among the developed countries whereas developing countries like Africa and Asia have highest predominant skin disease.
Nestle and Allergan had been the most active assignees in the year 2016. The patents/published applications majorly focus on novel compounds followed by vitamins as a part of dermatological composition. Nestle and GlaxoSmithKline were the most active assignees in the year 2017.The top priority country observed is China with a filing of 2752 patents followed by the US with 1179 patents/published applications, which indicates most innovations are originating in China. Interestingly, countries like Italy, Russia, Spain and Sweden are also active in the domain. Growth in dermatological market in the US in primarily driven due to variety of factors as such rising incidence of skin disease, rapid increase in healthcare expenditure and increasing awareness about aesthetic procedures. Growth in the dermatology market is witnessed at an increasing and accelerating pace in an upcoming and recent years.
This report covers most prevalent dermatological disorders, with a particular focus on major key diseases as: psoriasis, atopic dermatitis, acne vulgaris as these conditions have the highest prevalence and also has the largest pipeline. The global dermatology is expected to grow in billions in upcoming years. Key drivers of this growth will be the uptake of recently approved premium biologics, as well as promising late-stage products that are expected to be highly valuable, growing awareness among people with respect to aging and emphasis to look good and presentable and also increasing incidence of skin disease. Therefore, in nutshell the global dermatology market is expected to grow substantially due to promising novel product pipeline. The market size for dermatology therapeutics is expected to grow considerably, from $19.8 billion in 2016 to $41.2 billion in 2026, at a CAGR of 8 percent. Hence understanding the growth in patient epidemiology and market revenues for the dermatology market globally, among the key various players with respect to their product types is a major focus of the dermatology market outlook.
The key players dominating the dermatology market profiled in this report includes Novan, Vyome, Foamix, BioPharmX, Paratek, Sun Pharmaceuticals, Mankind, Cipla, Glenmark, Amgen, AbbVie, Valeant. Opportunity for the development of new products and services are high, as the market consists of recognized players and their big brands.
Key questions answered
We can customize the research for you, in case the report listed above does not meet with your requirements. Our custom research services provide clients with specific information they need to stay ahead of competition in today's fast paced business environment.